<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04147884</url>
  </required_header>
  <id_info>
    <org_study_id>S2436</org_study_id>
    <nct_id>NCT04147884</nct_id>
  </id_info>
  <brief_title>A Feasibility Study of the Millipede Transcatheter Annuloplasty Ring System in Patients With Functional Mitral Regurgitation</brief_title>
  <official_title>A Study to Evaluate the Feasibility and Safety of the Millipede Transcatheter Annuloplasty Ring System in Patients With Functional Mitral Regurgitation: (Millipede Feasibility Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the feasibility and safety of the Millipede Transcatheter Annuloplasty Ring&#xD;
      System in subjects with functional mitral regurgitation&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Millipede Feasibility Study is a prospective, open-label, single-arm study to assess the&#xD;
      safety and feasibility/performance of the Millipede Transcatheter Annuloplasty Ring System in&#xD;
      subjects with functional mitral regurgitation. The study will include subjects with&#xD;
      functional mitral regurgitation classified as moderate to severe (3+) or severe (4+) that are&#xD;
      symptomatic (NYHA Class II-IV) despite guideline directed medical therapy in whom the local&#xD;
      hearth team determines that surgery is not an option for mitral valve repair. Clinical&#xD;
      follow-up will be required in hospital, 30 days, 90 days, 6 months, 12 months, and then&#xD;
      annually through 5 years post-procedure. Subjects who have any part of the Millipede&#xD;
      Transcatheter Annuloplasty Ring System introduced into the body but who do not end up with an&#xD;
      implant will be followed through 30 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 13, 2019</start_date>
  <completion_date type="Anticipated">July 2027</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Technical Success Endpoint</measure>
    <time_frame>Index procedure exit from the catheterization laboratory</time_frame>
    <description>Technical Success (measured at exit from the catheterization laboratory) is defined per Mitral Valve Academic Research Consortium (MVARC ). All of the following must be present:&#xD;
Absence of procedural mortality; and Successful access, delivery and retrieval of the device delivery system; and Successful deployment and correct positioning of the first intended device; and Freedom from emergency surgery or reintervention related to the device or access procedure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Safety Endpoint</measure>
    <time_frame>30 days post index procedure</time_frame>
    <description>The composite (aggregate) of the following implant-related and/or delivery-related serious adverse events (SAEs) at 30 days post index procedure (based on MVARC definitions and adjudicated by an independent clinical events committee). The unit of outcome measure is % (n/N):&#xD;
Mortality: all-cause&#xD;
Stroke: disabling and non-disabling; Bleeding: life-threatening based MVARC scale&#xD;
Major access site vascular complications&#xD;
Major cardiac structural complications due to access-related issues&#xD;
Acute kidney injury (AKI; ≤7 days post index procedure): based on the Acute Kidney Injury Network (AKIN) --System Stage 3 (including renal replacement therapy) or Stage 2&#xD;
Myocardial infarction (MI; periprocedural [≤48 hours] or spontaneous [&gt;48 hours])&#xD;
Coronary ischemia requiring percutaneous coronary intervention (PCI) or coronary artery bypass graft&#xD;
Any valve-related dysfunction, migration, thrombosis, or other complication requiring surgery or repeat intervention</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Mitral Regurgitation Functional</condition>
  <condition>Mitral Valve Disease</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Mitral Valve Repair</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive mitral valve repair using the Millipede System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Millipede Transcatheter Annuloplasty Ring System (Millipede System)</intervention_name>
    <description>The Millipede Transcatheter Annuloplasty Ring System is a repair device used for treating mitral valve regurgitation (MR). The system consists of several components: a transcatheter annuloplasty ring (implant) which remains in the body and a delivery system and intracardiac echocardiography catheter (imaging device) used to deliver the implant to the mitral valve.</description>
    <arm_group_label>Mitral Valve Repair</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is 18 years of age or older&#xD;
&#xD;
          -  Subject (or legal guardian) understands the trial requirements and the treatment&#xD;
             procedures and provides written informed consent before any trial-specific tests or&#xD;
             procedures are performed&#xD;
&#xD;
          -  Subject has moderate to severe (3+) or severe (4+) functional mitral regurgitation&#xD;
             confirmed by echocardiography core lab&#xD;
&#xD;
          -  Subject is symptomatic (NYHA Class II-IV) despite guideline directed medical therapy,&#xD;
             including CRT if indicated&#xD;
&#xD;
          -  The local site heart team concurs that mitral valve surgery will not be offered as a&#xD;
             first-line treatment option&#xD;
&#xD;
          -  Subject is a candidate for annuloplasty based on the criteria below as assessed by the&#xD;
             investigative site (and confirmed by the Case Review Committee [CRC]):&#xD;
&#xD;
        Left Ventricular Ejection Fraction (LVEF) ≥ 25% Left Ventricular End Diastolic Diameter&#xD;
        (LVEDD) ≤ 65 mm Coaptation distance (i.e. tenting height) &lt; 10 mm Absence of posterior wall&#xD;
        aneurysm&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has severe calcification of the mitral annulus or leaflets or other anatomic&#xD;
             features that make the subject unsuitable for annuloplasty with the Millipede System&#xD;
             in the judgment of the treating physician or subject does not have suitable mitral&#xD;
             annular diameter (determined by CT) as per the Instructions for Use&#xD;
&#xD;
          -  Transfemoral venous and transseptal access determined not to be feasible&#xD;
&#xD;
          -  Subject is on the waiting list for a transplant or has had a prior heart transplant&#xD;
&#xD;
          -  Subject has had a cerebrovascular accident (CVA) or transient ischemic attack (TIA)&#xD;
             within 30 days prior to study enrollment&#xD;
&#xD;
          -  Subject has had any percutaneous coronary, carotid, or other endovascular intervention&#xD;
             within 30 days prior to study enrollment&#xD;
&#xD;
          -  Subject has had carotid surgery within 30 days prior to study enrollment&#xD;
&#xD;
          -  Subject has had any open coronary or vascular surgery (other than carotid surgery)&#xD;
             within 3 months prior to study enrollment&#xD;
&#xD;
          -  Subject has had a cardiac resynchronization therapy (CRT) device implantation within 3&#xD;
             months prior to study enrollment&#xD;
&#xD;
          -  Subject has untreated clinically significant coronary artery disease requiring&#xD;
             revascularization&#xD;
&#xD;
          -  Any planned cardiac surgery within the next 12 months&#xD;
&#xD;
          -  Need for emergent or urgent surgery for any reason&#xD;
&#xD;
          -  Subject has severe aortic valve stenosis and/or aortic valve regurgitation&#xD;
&#xD;
          -  Subject has physical evidence of right-sided congestive heart failure (CHF) with&#xD;
             echocardiographic evidence of moderate or severe right ventricular dysfunction and/or&#xD;
             severe tricuspid valve regurgitation&#xD;
&#xD;
          -  Subject has the presence of prosthetic heart valve in any position&#xD;
&#xD;
          -  Subject has renal insufficiency (eGFR &lt;20mL/min) and is not on dialysis&#xD;
&#xD;
          -  Subject has a life expectancy less than 12 months&#xD;
&#xD;
          -  Subjects in whom trans-esophageal echocardiography-Doppler assessment is&#xD;
             contraindicated or in which mitral regurgitation is not measurable by Transthoracic&#xD;
             Echocardiography (TTE)&#xD;
&#xD;
          -  Subject has a prior history of atrial septal defect (ASD) closure or patient foramen&#xD;
             ovale (PFO) closure&#xD;
&#xD;
          -  Subject has fixed pulmonary artery systolic pressure &gt; 70 mmHG&#xD;
&#xD;
          -  Subject has known hypersensitivity or contraindication to protocol required procedural&#xD;
             or post procedural medication (e.g., anticoagulation therapy) or hypersensitivity to&#xD;
             nickel or titanium&#xD;
&#xD;
          -  Subject has known hypersensitivity to contrast that cannot be adequately premedicated&#xD;
&#xD;
          -  Female subject who is breast feeding or is pregnant and planning to become pregnant&#xD;
             within the study period&#xD;
&#xD;
          -  Subject is participating in another investigational drug or device study that has not&#xD;
             reached its primary endpoint or subject intends to participate in another&#xD;
             investigational device clinical trial within 12 months after index procedure&#xD;
&#xD;
          -  Subject has a history of endocarditis within 6 months of index procedure or evidence&#xD;
             of an active systemic infection or sepsis&#xD;
&#xD;
          -  Subject has oxygen-dependent chronic obstructive pulmonary disease&#xD;
&#xD;
          -  Subject has documented severe liver disease&#xD;
&#xD;
          -  Subject has Hgb &lt;8 g/dL, platelet count &lt;50,000 cells/mm3 or &gt;700,000 cells/mm3, or&#xD;
             white blood cell count &lt;1,000 cells/mm3&#xD;
&#xD;
          -  Subject has any evidence of intracardiac thrombus&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Gooley, MBBS, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Monash Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicolas Van Mieghem, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Susheel K Kodali, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York-Presbyterian/Columbia University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Blessie Concepcion</last_name>
    <phone>800-876-9960</phone>
    <email>Blessie.Concepcion@bsci.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alison Osattin</last_name>
    <phone>800-876-9960</phone>
    <email>alison.osattin@bsci.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tucson Medical Center Healthcare</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalia Elias Calles, MPH</last_name>
      <phone>520-324-5512</phone>
      <email>natalia.eliascalles@tmcaz.com</email>
    </contact>
    <investigator>
      <last_name>Thomas E Waggoner, DO, FACC, FSCAI, FSVM, RPVI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gagan Singh, MD</last_name>
      <phone>916-734-3764</phone>
      <email>drsingh@ucdavis.edu</email>
    </contact>
    <investigator>
      <last_name>Gagan Singh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Los Robles Hospital &amp; Medical Center</name>
      <address>
        <city>Thousand Oaks</city>
        <state>California</state>
        <zip>91360</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cherry Papanicolaou</last_name>
      <phone>805-368-1803</phone>
      <email>cherry.papanicolaou@hcahealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Saibal Kar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Piedmont Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vinod Thourani, MD</last_name>
      <phone>404-605-2800</phone>
      <email>vinod.thourani@piedmont.org</email>
    </contact>
    <contact_backup>
      <last_name>Pradeep Yadav, MD</last_name>
      <phone>404-605-2800</phone>
      <email>pradeep.yadav@piedmont.org</email>
    </contact_backup>
    <investigator>
      <last_name>Vinod Thourani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pradeep Yadav, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Abbott Northwestern Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Nguyen</last_name>
      <phone>612-863-9291</phone>
      <email>jennifer.nguyen@allina.com</email>
    </contact>
    <investigator>
      <last_name>Paul Sorajja, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kara Booth</last_name>
      <phone>718-920-6523</phone>
      <email>kbooth@montefiore.org</email>
    </contact>
    <investigator>
      <last_name>Mohamed Azeem Latib, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center/New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kate Dalton</last_name>
      <phone>347-514-3366</phone>
      <email>Keb2114@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Susheel K Kodali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Prince Charles Hospital</name>
      <address>
        <city>Chermside</city>
        <state>Queensland</state>
        <zip>4032</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Raffel, MB, ChB, FRACP</last_name>
      <phone>(07) 3139 4000</phone>
      <email>Christopher.raffel@health.qld.gov.au</email>
    </contact>
    <investigator>
      <last_name>Christopher Raffel, MB, ChB, FRACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Gooley, MBBS</last_name>
      <phone>61 3 9594 2726</phone>
      <email>Robert.Gooley@monashhealth.org</email>
    </contact>
    <investigator>
      <last_name>Robert Gooley, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony Walton, MBBS</last_name>
      <phone>0414332444</phone>
      <email>twalton93@me.com</email>
    </contact>
    <investigator>
      <last_name>Anthony Walton, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Van Mieghem, Prof.</last_name>
      <phone>31-107039307</phone>
      <email>n.vanmieghem@erasmusmc.nl</email>
    </contact>
    <investigator>
      <last_name>Nicolas Van Mieghem, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Sussex County Hospital</name>
      <address>
        <city>Brighton</city>
        <zip>BN2 5BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Hildick-Smith, MD</last_name>
      <phone>441274000000</phone>
      <email>david.hildick-smith@nhs.net</email>
    </contact>
    <investigator>
      <last_name>David Hildick-Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Brompton Hospital</name>
      <address>
        <city>London</city>
        <zip>SW3 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Smith, MD</last_name>
      <phone>1895823737</phone>
      <email>r.smith@rbht.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Robert Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 30, 2019</study_first_submitted>
  <study_first_submitted_qc>October 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2019</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Functional Mitral Regurgitation</keyword>
  <keyword>Mitral Repair</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>The data and study protocol for this clinical trial may be made available to other researchers in accordance with the Boston Scientific Data Sharing Policy (http://www.bostonscientific.com/en-US/data-sharing-requests.html)</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

